Condition: Type 2 Diabetes Mellitus (T2DM) · Non-Alcoholic Fatty Liver Disease (NAFLD) · Sponsor: 1Globe Health Institute
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.
This description comes directly from the study's public registry record.
1Globe Health Institute · 617-649-1157 · T2DM-QX1206-1_Study@1globe-usa.com
Always discuss trial participation with your own doctor first.
| Centricity Research Toronto LMC. | Toronto, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06694935